Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib/II open-label multicenter study of the safety, pharmacokinetics, and efficacy of APO2L/Trail administered intravenously in combination with rituximab to subjects with follicular and other low-grade, CD20+, B-cell non-Hodgkin's lymphomas that have progressed following previous rituximab therapy.

Next Previous
X
Search
Trial Profile

A Phase Ib/II open-label multicenter study of the safety, pharmacokinetics, and efficacy of APO2L/Trail administered intravenously in combination with rituximab to subjects with follicular and other low-grade, CD20+, B-cell non-Hodgkin's lymphomas that have progressed following previous rituximab therapy.

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 01 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dulanermin (Primary) ; Rituximab
  • Indications B-cell lymphoma; Follicular lymphoma
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Genentech

    • Most Recent Events

    • 01 Apr 2022 This trial has been completed in France, according to European Clinical Trials Database record.
    • 29 Jun 2012 Additional trial locations added as reported by European Clinical Trials Database.
    • 09 Jun 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top